Eleni Efstathiou, MD, PhD, from the The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the need for treatment of prostate cancer to be carried out earlier in disease progression rather than later. Treatments that are being developed for advanced cancers need to be translated into early stage cancer, where the landscape for mutation is less rich, and treatment will have a more meaningful impact on patient lives. Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL.